Amphotericin B liposomal indications and usage: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Amphotericin B liposomal}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Indications and Usage== | |||
AmBisome is indicated for the following: | |||
*:Empirical therapy for presumed fungal infection in febrile, '''[[neutropenic patients]]'''. | |||
*:Treatment of '''Cryptococcal [[Meningitis]]''' in HIV infected patients. | |||
Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. | |||
Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES). | |||
See DOSAGE AND ADMINISTRATION for recommended doses by indication. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher = | date = | accessdate = }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 15:39, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
AmBisome is indicated for the following:
- Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
- Treatment of Cryptococcal Meningitis in HIV infected patients.
Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES).
See DOSAGE AND ADMINISTRATION for recommended doses by indication. [1]
References
Adapted from the FDA Package Insert.